drugset
drugset / Trial / NCT05148442

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

NCT05148442 ↗

Phase 1 Terminated 1 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in Myeloid tumor patients.

Timeline

Start
2021-12-28
Primary completion
2023-06-19
Completion
2023-08-29

Outcome

Outcome not reported

Stopped (Business): “Due to the company's development strategy adjustment\]”

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI322 Monoclonal antibody — —

Indications

myeloid neoplasm